FN1 and glioblastoma: Given fibronectin’s pivotal role in these oncogenic processes, its cellular receptors, integrins, have emerged as highly promising targets for novel GBM interventions, spanning from direct therapeutics and drug delivery systems to imaging-based diagnostics.